Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hunan Warrant Pharmaceutical Co.,Ltd (688799.SS)
Changsha, CN
Hunan Warrant Pharmaceutical Co., Ltd. is engaged in the manufacturing and commercialization of pharmaceutical products. Its extensive product line encompasses treatments addressing immune and kidney-related conditions, obstetrics and gynecology, cardiovascular health, and digestive system issues. The company also offers a range of anti-infective medications and remedies for various other ailments. Established in 2001, it is headquartered in Changsha, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.31% | -7.36% | -14.42% | +13.21% | +3.82% | +5.28% | +8.33% | +73.83% | +30.20% | +30.20% | +30.20% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-08 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+7.3% ★ Q1'26: -3.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+47.2% ★ Q1'26: -35.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+17.0% ★ Q1'26: -35.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+16.2% ★ Q1'26: +10.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.4% ★ Q1'26: +4.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.2% ★ Q1'26: +2.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.58× Q1'26: 4.89× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
1.43B
est: 1.43B (+0.3%)
|
1.41B
est: 1.41B (0.0%)
|
1.52B
est: 1.43B (+6.3%)
|
1.61B
1.61B – 1.61B
+12.6% YoY
|
1.73B
1.73B – 1.73B
+7.5% YoY
|
1.87B
1.87B – 1.87B
+8.2% YoY
|
| EBITDA |
291.02M
est: 243.71M (+19.4%)
|
230.60M
est: 304.35M (-24.2%)
|
314.45M
est: 307.15M (+2.4%)
|
345.92M
345.92M – 345.92M
+12.6% YoY
|
371.77M
371.77M – 371.77M
+7.5% YoY
|
402.36M
402.36M – 402.36M
+8.2% YoY
|
| EBIT |
230.00M
est: 189.36M (+21.5%)
|
161.69M
est: 210.56M (-23.2%)
|
245.55M
est: 212.50M (+15.6%)
|
239.32M
239.32M – 239.32M
+12.6% YoY
|
257.20M
257.20M – 257.20M
+7.5% YoY
|
278.36M
278.36M – 278.36M
+8.2% YoY
|
| Net Income |
211.32M
est: 150.90M (+40.0%)
|
164.32M
est: 172.48M (-4.7%)
|
241.47M
est: 227.03M (+6.4%)
|
186.35M
186.35M – 186.35M
-17.9% YoY
|
209.97M
209.97M – 209.97M
+12.7% YoY
|
245.40M
245.40M – 245.40M
+16.9% YoY
|
| SGA |
595.34M
est: 645.71M (-7.8%)
|
547.26M
est: 501.59M (+9.1%)
|
—
est: 506.20M (-100.0%)
|
570.10M
570.10M – 570.10M
+12.6% YoY
|
612.70M
612.70M – 612.70M
+7.5% YoY
|
663.10M
663.10M – 663.10M
+8.2% YoY
|
| EPS |
1.61
est: 1.61 (+0.2%)
|
1.25
est: 1.31 (-4.9%)
|
1.84
est: 1.73 (+6.4%)
|
1.42
1.42 – 1.42
-17.9% YoY
|
1.60
1.60 – 1.60
+12.7% YoY
|
1.87
1.87 – 1.87
+16.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ben Dong Huang | Chairman & GM | — | male |
| Dou Lin | Deputy General Manager | — | female |
| Gui Ying Wu | Financial Director & Accounting Supervisor | — | female |
| Jian Xiao | Deputy General Manager | — | male |
| Qiao Qiao | Secretary to the Board | — | male |
| Xiang Gao | Director & Deputy GM | — | male |
| Yue Tan | Core Technical staff | — | male |
| Zhigang Zhou | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688799.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
